Table 1.
Demographics of respondents in each country (N = 15 per country)
| France | Germany | Italy | Spain | UK | Total | |
|---|---|---|---|---|---|---|
| N = 15 | N = 15 | N = 15 | N = 15 | N = 15 | N = 75 | |
| Speciality, n (%) | ||||||
| Oncologist | 5 (33) | 1 (7) | 3 (20) | 0 (0) | 0 (0) | 9 (12) |
| Haematologist | 5 (33) | 2 (13) | 7 (47) | 8 (53) | 8 (53) | 30 (40) |
| Haemato-oncologist | 5 (33) | 12 (80) | 5 (33) | 7 (47) | 7 (47) | 36 (48) |
| Location, n (%) | ||||||
| University hospital | 7 (47) | 10 (67) | 7 (47) | 13 (86) | 11 (73) | 48 (64) |
| Cancer hospital/specialist centre | 6 (40) | 4 (27) | 5 (33) | 0 (0) | 2 (13) | 17 (23) |
| Community/urban/general hospital | 2 (13) | 1 (7) | 3 (20) | 2 (13) | 2 (13) | 10 (13) |
| Experience, years | ||||||
| Years treating adults with ALL, median (range) | 15 (7–29) | 12 (8–18) | 10 (6–30) | 16 (9–34) | 12 (17–20) | N/A |
| Caseloada of ALL subtypes from 12 months before the survey, n | ||||||
| ALL, median (range) | 30 (3–200) | 20 (6–100) | 30 (5–100) | 20 (3–230) | 24 (4–200) | N/A |
| R/R Ph(–) B-precursor ALL, median (range) | 8 (1–75) | 3 (1–21) | 5 (1–50) | 4 (0–55) | 4 (1–50) | N/A |
aNumber of patients
ALL acute lymphoblastic leukaemia, N/A not available, Ph(–) Philadelphia negative, R/R relapsed or refractory